High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis

Alessio Baricich; Elisa Grana; Stefano Carda; Andrea Santamato; Carlo Cisari; Marco Invernizzi

doi:10.1007/s00702-015-1384-6

High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis

Alessio Baricich
, Elisa Grana
, Stefano Carda
, Andrea Santamato
, Carlo Cisari
, Marco Invernizzi

Department of Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

We retrospectively evaluated the efficacy and safety of high doses of onabotulinumtoxinA (from 600 to 800 units) in 26 patients affected by upper and/or lower limb post-stroke spasticity. They were assessed before, 30 and 90 days after treatment. We observed a significant muscle tone reduction and a significant functional improvement (assessed with the Disability Assessment Scale). No adverse events were reported. In our retrospective analysis the treatment with high doses of onabotulinumtoxinA showed to be effective and safe.

Original language	English
Pages (from-to)	1283-1287
Number of pages	5
Journal	Journal of Neural Transmission
Volume	122
Issue number	9
DOIs	https://doi.org/10.1007/s00702-015-1384-6
Publication status	Published - 21 Sept 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Botulinum toxin type A
Higher doses
OnabotulinumtoxinA
Spasticity
Stroke

Access to Document

10.1007/s00702-015-1384-6

Cite this

@article{709ae5b5d4d449e8841193650cd6f381,

title = "High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis",

abstract = "We retrospectively evaluated the efficacy and safety of high doses of onabotulinumtoxinA (from 600 to 800 units) in 26 patients affected by upper and/or lower limb post-stroke spasticity. They were assessed before, 30 and 90 days after treatment. We observed a significant muscle tone reduction and a significant functional improvement (assessed with the Disability Assessment Scale). No adverse events were reported. In our retrospective analysis the treatment with high doses of onabotulinumtoxinA showed to be effective and safe.",

keywords = "Botulinum toxin type A, Higher doses, OnabotulinumtoxinA, Spasticity, Stroke",

author = "Alessio Baricich and Elisa Grana and Stefano Carda and Andrea Santamato and Carlo Cisari and Marco Invernizzi",

note = "Publisher Copyright: {\textcopyright} 2015, Springer-Verlag Wien.",

year = "2015",

month = sep,

day = "21",

doi = "10.1007/s00702-015-1384-6",

language = "English",

volume = "122",

pages = "1283--1287",

journal = "Journal of Neural Transmission",

issn = "0300-9564",

publisher = "Springer",

number = "9",

}

TY - JOUR

T1 - High doses of onabotulinumtoxinA in post-stroke spasticity

T2 - a retrospective analysis

AU - Baricich, Alessio

AU - Grana, Elisa

AU - Carda, Stefano

AU - Santamato, Andrea

AU - Cisari, Carlo

AU - Invernizzi, Marco

PY - 2015/9/21

Y1 - 2015/9/21

N2 - We retrospectively evaluated the efficacy and safety of high doses of onabotulinumtoxinA (from 600 to 800 units) in 26 patients affected by upper and/or lower limb post-stroke spasticity. They were assessed before, 30 and 90 days after treatment. We observed a significant muscle tone reduction and a significant functional improvement (assessed with the Disability Assessment Scale). No adverse events were reported. In our retrospective analysis the treatment with high doses of onabotulinumtoxinA showed to be effective and safe.

AB - We retrospectively evaluated the efficacy and safety of high doses of onabotulinumtoxinA (from 600 to 800 units) in 26 patients affected by upper and/or lower limb post-stroke spasticity. They were assessed before, 30 and 90 days after treatment. We observed a significant muscle tone reduction and a significant functional improvement (assessed with the Disability Assessment Scale). No adverse events were reported. In our retrospective analysis the treatment with high doses of onabotulinumtoxinA showed to be effective and safe.

KW - Botulinum toxin type A

KW - Higher doses

KW - OnabotulinumtoxinA

KW - Spasticity

KW - Stroke

UR - https://www.scopus.com/pages/publications/84939573418

U2 - 10.1007/s00702-015-1384-6

DO - 10.1007/s00702-015-1384-6

M3 - Article

SN - 0300-9564

VL - 122

SP - 1283

EP - 1287

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

IS - 9

ER -

High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this